August 23, 2018 / 5:23 AM / 3 months ago

BRIEF-Novartis says PI3K inhibitor meets primary endpoint in breast cancer

Aug 23 (Reuters) - Novartis AG:

* SAYS SOLAR-1 TRIAL OF INVESTIGATIONAL ALPHA-SPECIFIC PI3K INHIBITOR BYL719 (ALPELISIB) MEETS PRIMARY ENDPOINT IN HR+/HER2- ADVANCED BREAST CANCER WITH PIK3CA MUTATION

* SAYS FULL RESULTS WILL BE SUBMITTED TO AN UPCOMING MEDICAL CONGRESS AND NOVARTIS WILL INITIATE DISCUSSIONS WITH REGULATORY AUTHORITIES WORLDWIDE Further company coverage: (Reporting By Zurich newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below